San Diego, CA, United States of America

Erika Olson

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Sanford Burnham Prebys Medical Discovery Institute, Scripps Research Institute. Active years: 2019.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erika Olson: Innovator in Neuroprotection

Introduction

Erika Olson is a prominent inventor based in San Diego, CA, known for her significant contributions to the field of neuroprotection and neural repair. With a focus on developing innovative therapeutic solutions, she has made strides in addressing EphA4-based diseases and disorders.

Latest Patents

Erika Olson holds a patent for "EPHA4 cyclic peptide antagonists for neuroprotection and neural repair." This patent discloses APY cyclic peptides that exhibit EphA4 antagonistic activity. The pharmaceutical compositions containing these EphA4 antagonists are designed for treating various EphA4-based diseases, disorders, or pathologies in individuals.

Career Highlights

Throughout her career, Erika has worked with esteemed institutions such as the Sanford Burnham Prebys Medical Discovery Institute and The Scripps Research Institute. Her work in these organizations has allowed her to collaborate with leading scientists and contribute to groundbreaking research in her field.

Collaborations

Erika has collaborated with notable colleagues, including Elena B. Pasquale and Philip E. Dawson. These partnerships have further enhanced her research and innovation efforts.

Conclusion

Erika Olson's work in developing EphA4 cyclic peptide antagonists represents a significant advancement in neuroprotection and neural repair. Her contributions continue to impact the scientific community and pave the way for future innovations in treating neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…